Olendalizumab 产品活性：Olendalizumab (ALXN1007) 是一种源自小鼠的人源化 IgG2-G4-κ 抗体，靶向补体蛋白 C5a (Ki=60 pM)。Olendalizumab 靶向补体炎症通路。并且，Olendalizumab 可用于研究由冠状病毒引起的补体介导的疾病。 产品来源： https://www.medchemexpress.cn/olendalizumab.html 研究领域：Immunology/Inflammation 作用靶点：Complement System In Vitro: Olendalizumab can be used as an biotinylated capture reagent, with working concentration of 100 μg/mL in Bioaffy wash 1, while the AlexaFluor labeled anti-C5a clone 2942 is 4 μg/mL in Rexxip F. The members of the complement system such as C3, C5a, C5b-9, including receptors such as C3aR and C5aR mediate the lung injury following viral infection. Moreover, C5/C5a is only non-silent complement in corona virus-induced lung injury. Olendalizumab is the potent C5a inhibitor. 相关产品：Dexamethasone | Cyclosporin A | SB290157 trifluoroacetate | Iptacopan | PMX-53 | EG00229 | JR14a | Danicopan | PMX 205 Trifluoroacetate | Compstatin | AMY-101 acetate | EG01377 dihydrochloride | Leukadherin-1 | Eculizumab | JPE-1375 | Vesencumab | TLQP-21 TFA | Avacopan | Avacincaptad pegol sodium | Sutimlimab | W-54011 | C3a receptor agonist 1 | Complement C5-IN-1 | POT-4 | Vemircopan | Certepetide 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。